Uitgebreide indicatie |
Two pediatric indications: 1) Rozlytrek as monotherapy for the treatment of paediatric patients with solid tumours that have a ROS1 gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have not received a prior ROS1 inhibitor, and who have no satisfactory treatment options. 2) indication extension to pediatric patients <12 years with solid tumours that have a NTRK gene fusion who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor, and who have no satisfactory treatment options.
|